Treatment-Refractory Advanced Urothelial Cancer: What to Do After Chemotherapy and/or Immunotherapy

Download slides by Arjun Balar, MD on the role of antibody-drug conjugates in advanced urothelial cancer following chemotherapy and immunotherapy.
person default
Arjun Balar, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 804 KB
Released: May 4, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bristol-Myers Squibb
Pfizer, Inc. and EMD Serono

Related Content

Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)

person default Eva Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 15, 2021

A downloadable slideset on new approaches to managing low-grade upper tract urothelial cancer from Clinical Care Options (CCO).

Surena Matin, MD Released: September 10, 2021

Slides from Clinical Care Options (CCO) on 2021 treatment recommendations for patients with nmCRPC.

David F. Penson, MD Released: September 10, 2021

A downloadable slideset from Clinical Care Options (CCO) focused on the latest evidence for managing non-muscle invasive bladder cancer (NMIBC).

Seth P. Lerner, MD Released: September 10, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue